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BACKGROUND: Epidemiological and in vitro data implicate androgens in the aetiology of ovarian cancer, but the mechanisms by which
this is mediated are unclear. In this study, we wished to examine the effects of androgens on gene expression in ovarian cancer.
METHODS: The expression of androgen receptor (AR) in OVCAR3 and OSEC2 cells was confirmed using immunoblotting and
response to androgens was measured using flow cytometric assessment of S-phase fraction. The differential gene expression
between androgen stimulated and unstimulated OVCAR3 ovarian cancer cells was examined with a cDNA microarray. The
upregulation of a subset of these genes was then confirmed with reverse transcriptase PCR in both OVCAR3 and OSEC2, an ovarian
epithelial cell line. Finally, the clinical significance of this upregulation was investigated by examining the expression of Rab25 and
Rab35, two G-protein-related molecules in an ovarian cancer tissue microarray (TMA).
RESULTS: OVCAR3 and OSEC2 cells were shown to express the AR and showed an increase in S-phase fraction in response to
androgen treatment. Treatment of OVCAR3 cells with androgen resulted in a significant upregulation of 121 genes. These findings
were confirmed for a subset of seven monomeric G-protein-related genes in both OVCAR3 and OSEC2 cells. After staining for
Rab25 and Rab35, the majority of TMA sections examined showed expression for Rab25 (92%) and Rab35 (95%). The expression of
Rab25 correlated with histological grade, and expression was higher in endometrioid (median histoscore 10.5) than serous (7.5) or
mucinous (5.3) tumours. The expression of Rab25 correlated positively with AR expression supporting its role as an androgen
responsive gene in ovarian cancer.
CONCLUSIONS: These results suggest that androgens can effect expression of the oncogenic GTPases in ovarian cancer. We propose
that the androgen responsive Rab35 may have clinical importance as a biomarker of AR function.
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There is a wealth of evidence to suggest that many epithelial ovarian
cancers (EOC) are hormonally related (Lukanova and Kaaks, 2005).
Epithelial ovarian cancer is thought to arise from the ovarian surface
epithelium (OSE), a single layer of cells overlying the ovary, which is
in close proximity to the hormone-producing cells of the ovary.
Many cancers are proposed to arise from invaginations of the OSE,
which follow ovulation and create inclusion cysts (Auersperg et al,
2001). The cells lining these cysts lack a tunica albuginea, and are
therefore exposed to even higher levels of steroid hormones,
including oestrogens, progesterones and androgens.
Epidemiological evidence suggesting that hyperandrogenic
states are associated with the development of EOC (Schildkraut
et al, 1996; Wang and Chang, 2004; Gaducci et al, 2005) has led to
the development of the androgenic theory of ovarian cancer
development (Risch, 1998). Androgens exert their effects through
activation of the androgen receptor (AR), a type I nuclear hormone
receptor, involved in gene transcription. The action of AR is
controlled by a series of coregulators (Gnanapragasam et al, 2000).
We have previously shown that OSE cells express the AR and
respond to androgen stimulation resulting in increased prolifera-
tion and protection from apoptosis (Edmondson et al, 2002),
others have shown that the majority of ovarian cancers continue to
express the AR (Kuhnel et al, 1987; Ilekis et al, 1997; Lee et al,
2005). Other phenotypic effects of androgens on ovarian cancer
cells and how these are mediated are poorly understood, although
it has been shown that androgen treatment allows these cells to
escape the growth inhibitory effect of transforming growth factor b
(TGFb) by downregulating the expression of the TGF receptors,
TGFbR I and II (Evangelou et al, 2000). Androgen stimulation also
results in changes in expression of the steroid hormone
coregulators, SRC-1, ARA70 and AIB1, although this cofactor is
lost in the neoplastic transformation of OSE cells to EOC
(Evangelou et al, 2003).
Here, we investigate the effects of androgens on gene expression
in cells expressing the AR, and investigate the clinical relevance of
the subsequently identified androgen responsive genes.
MATERIALS AND METHODS
Tissue microarray
The Newcastle ovarian cancer tissue microarray (TMA) has been
described previously (Wilkinson et al, 2008). Briefly, the TMA
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comprises 154 cases of histologically confirmed EOC, with accom-
panying clinical data available for each case. All tissue samples were
taken from sequential patients who underwent primary surgery
between 1995 and 2000 at the Northern Gynaecological Oncology
Centre, Gateshead, UK, with appropriate ethical approval. All patients
underwent maximal-effort primary cytoreductive surgery followed by
platinum-based chemotherapy with or without paclitaxel.
Cell lines and cell culture
OVCAR3 cells were obtained from the American Tissue and Cell
Collection and maintained in RPMI-1640 medium (Sigma-Aldrich,
Poole, UK) with the addition of 20% (v/v) foetal bovine serum
(Sigma-Aldrich) and 1% L-Glutamine (20mM) (Sigma-Aldrich).
OSEC2 cells have been previously described (Davies et al, 2003).
Briefly this cell line was derived from a primary culture of normal
ovarian epithelial cells created following an oophorectomy for
a non-malignant pathology. Cells were immortalised using hTERT
and the temperature-sensitive form of SV40 large T antigen.
OSEC2 cells are maintained at the permissive temperature of 301C
in RPMI-1640 medium (Sigma-Aldrich) with the addition of 10%
foetal bovine serum (Sigma-Aldrich) and 1% L-Glutamine (20mM)
(Sigma-Aldrich).
Cell proliferation assays
Cell cycle analysis was carried out using flow cytometry. After
stimulation with dihydrotestosterone (DHT), cells were harvested,
washed in PBS and resuspended in a propidium iodide (PI)
solution (RNAase (1%w/v), PI (18%w/v), FCS (2%v/v) in 5%
Triton) for 30min before being analysed on a Becton-Dickinson
FACScan Flow Cytometer (BD Becton-Dickinson UK Limited,
Oxford, UK). Data were analysed using WinMidi software (Scripps
Institute, San Diego, CA, USA).
Cell proliferation was measured using a sulphorhodamine B
(SRB) assay. Briefly, cells were seeded in 96-well plates, washed
with PBS and quiesced in serum-free medium for 48 h before DHT
treatment. Cells were fixed with 50% trichloroacetic acid and
stained with 0.4% SRB solution before the addition of10mM Tris.
All plates were analysed on a spectrophotometer at 570 nm. Data
presented are the results of six independent experiments.
Western blotting
Cells were harvested in lysis buffer (1%Triton-X, 0.1% sodium
dodecyl sulphate, 0.5% sodium deoxycholate) and were fractio-
nated using SDS-PAGE in a mini-protean III system (BioRad,
Herts, UK) followed by electrotransfer onto nitrocellulose mem-
brane (Hydrobond C, Amersham Biosciences, Amersham, UK).
Membranes were incubated overnight at 41C with mouse
monoclonal anti-human AR antibody, at a concentration of
1 : 1000 (clone AR441, Dako, Glostrup, Denmark). Blots were
reprobed with anti-a-tubulin antibody (1 : 2000)(Dako) to confirm
equal loading of protein.
The immunocomplex was detected using appropriate secondary
antibodies and visualised using enhanced chemiluminescence
detection system (ECL)(Amersham Biosciences).
cDNA microarray analysis and real-time RT-PCR
Total RNA was extracted from DHT stimulated and unstimulated
OVCAR3 cells using a commercially available kit (RNeasy, Qiagen,
Crawley, UK). Concentrations of RNA 41000ngml1 were used
for cDNA microarray analysis (Human Genome U133 Plus 2.00
gene chip, Affymetrix, High Wycombe, UK). Data were normalised
and analysed using Genespring software (Agilent Technologies,
Edinburgh, UK). A twofold change in gene expression compared
with unstimulated cells was considered significant. Ontological
analysis was performed using the Netaffx database (http://Affymetrix.
com/). Quantitative real-time RT-PCR analysis was performed using
Jumpstart SYBR Green master mix (Sigma-Aldrich) and specific
primers (VH Bio Ltd, Gateshead, UK) were designed using Primer
Express software (version 2.0, Applied Biosystems Inc. Foster City,
CA, USA). Expression levels were normalised against a housekeeping
gene, GAPDH. All QPCR experiments were performed on a 7900-HT
sequence detection system and integral SDS software (Applied
Biosystems, Warrington, UK) was used for analysis.
Immunohistochemistry
Tissue microarray sections were deparaffinised and rehydrated
through a series of graded alcohols. Antigen retrieval was achieved
by the pressure cooker method in 0.01 M citrate buffer (pH 6.0).
Slides were then washed in PBS before being treated with a 1.7%
hydrogen peroxide/methanol solution. A total of 10% blocking
serum was applied for 20min at room temperature before
application of the primary antibody overnight at 41C. Monoclonal
mouse anti-human AR antibody was used at a concentration of
1 : 20 (clone 441, Santa Cruz, Heidelberg, Germany). Monoclonal
mouse anti-human Rab25 antibody was used at a concentration of
1 : 500 (clone 3F12F3, ProMab Biotechnologies, Richmond, CA,
USA). Polyclonal rabbit anti-human Rab35 antibody was used at a
concentration of 1 : 20 (Proteintech, Manchester, Peterborough, UK).
Primary antibody was detected with an appropriate biotin-con-
jugated secondary antibody (Vector Laboratories, Peterborough,
UK). Slides were then developed using an avidin–biotin–peroxidase
complex kit (Vectastain, Vector Laboratories), incubated with 30,30-
diaminobenzidine (Sigma-Aldrich), counterstained using Harris’
haematoxylin before being dehydrated and mounted. Negative
control sections were incubated with secondary antibody alone.
Tissue controls included prostate, breast and thyroid tissues for AR,
Rab25 and Rab35, respectively. Each core was independently scored
by two of the authors (EMA and RJE) using a modified H-score
(Leake et al, 2000). The H-score is a multiplicative score generated by
two parameters, namely maximal intensity of staining and percen-
tage area of the section stained. Scores range from 0 (no staining
throughout the section) to 18 (high intensity staining throughout the
whole section). Any differences of opinion were mutually resolved,
For the purpose of analysis, scores were further categorised as low
(less than median score) or high (greater than median score).
Statistics
Statistical analysis was performed using SPSS version 11.0 (SPSS
Inc., Chicago, IL, USA). Statistical significance was evaluated using
the log-rank test, non-parametric analysis by Kruskal–Wallis,
Kaplan–Meier analysis for survival and Cox regression for multi-
variate analysis. A P-value of o0.05 was considered statistically
significant. Correlation was analysed using Spearman’s correlation.
RESULTS
OVCAR 3 and OSEC2 cells express AR and are responsive
to androgen stimulation
The presence of AR in OVCAR3 and OSEC2 cells was confirmed
using western blot of nuclear and cytoplasmic extracts after DHT
treatment. Androgen receptor protein was found to be exclusively
nuclear, in keeping with a functional protein (Figure 1).
Stimulation of OSEC2 and OVCAR3 cells with increasing doses of
DHT for 24 h resulted in an increase in cell proliferation of up to 25%
over unstimulated cells (Figure 2A). This observed increase was
abrogated with the addition of the AR-specific antagonist, Casodex,
suggesting that this effect is AR dependent (Figure 2B). Stimulation
of OVCAR3 cells with increasing doses of DHT for 24 h results in an
increase in the S-phase fraction over unstimulated cells (Figure 2C).
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Androgen stimulation promotes differential expression of
multiple genes
Messenger RNA was extracted from OVCAR3 cells that were either
untreated or exposed to 10 nM of DHT for 2 or 8 h. Microarray
analysis was then performed using the Affymetrix u133 gene chips
(Affymetrix) and the expression was compared with that of non-
stimulated cells. Results were normalised and analysed using
Genespring software. Stimulation with DHT resulted in greater
than twofold upregulation of 33 and 105 genes at 2 and 8 h,
respectively, and downregulation of 1 and 16 genes at 2 and 8 h,
respectively. Seven genes were upregulated at both 2- and 8-h time
points.
Ontological analysis of the upregulated genes indicated that
the majority were related to gene transcription, but some genes
associated with proliferation and G-protein signalling were also
found to be increased compared with the untreated controls
(Table 1).
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Figure 2 Treatment with DHT results in an increase in cell proliferation in both normal and malignant ovarian cells. (A) OSEC2 and OVCAR 3 cells were
stimulated for 24 h with DHT before analysis using an SRB assay. Both cell lines show increases in cell proliferation after DHT stimulation of up to 24 h.
Increased cell proliferation is shown using a dose of 10 nM in the OSEC2 cells, but a dose of 100 nM in OVCAR3 cells. (B) OVCAR3 cells were treated for
24 h with 10 nM DHT in the presence and absence of the specific AR inhibitor, Casodex, before analysis using an SRB assay. The androgen-induced
stimulation is abrogated by the addition of Casodex. Casodex alone had no effect on cell proliferation. (C) OVCAR3 cells were treated with DHT for 24 h
and the S-phase fraction analysed using propidium iodide incorporation. Cells stimulated with DHT show a dose-dependent increase in the S-phase fraction
compared with non-treated cells.
Table 1 Ontological classification of genes upregulated in OVCAR3 cells
after exposure to 10 nM DHT
Ontological group 2h 8h Both Total
Transcription 19 47 3 63
Proliferation 7 14 1 20
G-protein signalling 3 12 2 13
Apoptosis 1 17 0 18
Ubiquitination 1 7 1 7
Cell adhesion 2 8 0 10
Total 33 105 131
DHT¼ dihydrotestosterone.
100 kDa AR
50 kDa -tubulin
98 kDa PARP
Cytoplasm Nucleus
Figure 1 Western blot showing nuclear and cytoplasmic fractions of
OVCAR3 cells after treatment with 10 nM DHT. Androgen receptor (AR)
is expressed in the nuclear fraction, as confirmed by the presence of PARP,
in contrast to the cytoplasmic fraction suggesting the presence of
functionally active protein.
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Upregulation of mRNA expression was confirmed in a subset of
eight G-protein-related genes using RT-PCR. Changes in mRNA
levels of G-protein-related genes in both OVCAR3 and OSEC2 cells
after stimulation with 10 nM of DHT for 2, 4, 8, and 12 h confirmed
the data obtained from the microarray experiment for the subset of
genes tested (Table 2).
Rab25, Rab35 and AR are expressed by ovarian cancers
In light of the finding that G-proteins were upregulated in response
to androgen stimulation, we decided to further investigate the
expression of two of these proteins in clinical ovarian cancer
samples. Rab35 was chosen as it was the most highly upregulated
gene in the cDNA microarray experiment, and Rab25 was chosen
as this protein has been linked with ovarian cancer (Cheng et al,
2004a, b; Cheng et al, 2005).
Clinical characteristics of the patient samples included in the
TMA have been previously published (Wilkinson et al, 2008). The
TMA was stained for AR expression (Figure 3). As expected,
staining was predominantly nuclear, 86% of samples showed
positivity for AR. Androgen receptor scores showed no correlation
with FIGO stage, histological subtype, residual disease, preopera-
tive CA125 levels or overall survival.
The TMA was then stained for Rab25 expression (Figure 3). The
majority of staining was cytoplasmic, with 92% of samples showing
positivity for Rab25. Rab25 scores were higher in endometrioid
tumours (median score 10.5) compared with serous (median score
7.5), mucinous (median score 5.3) and clear cell (median score 5.8)
tumours, but there was no correlation with FIGO stage or residual
disease (Table 3). Overall, Rab25 expression did not correlate with
survival, but when classified by histological subtype, high
expressors (expression greater than the median score (7.5))
showed variation by histological subtype unlike low expressors,
which showed no variation in survival (Figure 4).
The TMA was stained for Rab35 expression (Figure 3). As
expected, staining was entirely cytoplasmic, 95% of samples
showed positivity for Rab35. Rab35 scores showed no correlation
with FIGO stage, histological subtype, residual disease, preopera-
tive CA125 levels or overall survival when analysed by high and
low expressors (high expressors defined as expression greater than
the median score (4.7)).
Finally, correlation was investigated between scores for AR,
Rab25 and Rab35 expression. No significant correlation was found
between Rab25 and AR expression, but a significant positive
correlation was seen between Rab35 and AR expression, (r¼ 0.23,
Po0.01).
DISCUSSION
We have described here the effects of the androgen DHT on both
cell proliferation and gene expression in ovarian cancer cells. This
physiologically important hormone has been linked with ovarian
cancer; however, this is the first study investigating the effects of
acute exposure to androgens on gene expression. The findings
are therefore likely to differ from other studies in which gene
Table 2 Changes in expression of G-proteins after 8-h stimulation by 10 nM DHT
Maximal fold change upregulation
OVCAR3 OSEC2
Gene Accession number Brief description of known function Affymetrix RT-PCR RT-PCR
GNA13 NM_006572 a-Subunit of heterotrimeric G-protein 13 2.2 5.5 146.1
ELKS AB029004 RAB6-interacting protein 2. Regulator of NF-kB signalling 2.9 2 1.4
GSTP1 BE544748 G to S-phase transition protein 1 2.5 2 7.8
RERG AW294092 Monomeric G-protein 2.9 3 5.2
Rab25 NM_020387 Monomeric G-protein. Involved in vesicle trafficking 1.05 1.42 ND
Rab45 NM_152573 Monomeric G-protein. Involved in vesicle trafficking 2.5 2.5 8.6
Rab35 NM_006861 Monomeric G-protein. Involved in vesicle trafficking 5.4 13 13.1
DHT¼ dihydrotestosterone; NF-kB¼ nuclear factor kB; RT-PCR¼ reverse transcriptase PCR.
ARRab 25 Rab 35
Ovarian
cancer
Positive
control
Figure 3 Rab25, Rab35 and AR expression in clinical samples. Rab25, Rab35 and AR protein expression levels were determined using
immunohistochemical techniques for 154 epithelial cancer samples arrayed on a TMA. Representative sections are shown demonstrating predominantly
cytoplasmic staining for Rab25 and Rab35, and nuclear staining for AR. Breast, thyroid and prostate sections were used as positive controls for Rab25, Rab35
and AR, respectively.
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expression was analysed after chronic exposure to androgens
(Motamed-Khorasani et al, 2007).
We have shown that, in addition to some predicted increases in
gene expression in genes encoding proteins related to transcription
regulation and cell cycle control, there was also an increase in the
expression of several proteins related to G-protein signalling. The
G-proteins are a superfamily of ubiquitous signalling molecules.
They are involved in intracellular signalling from G-protein-
coupled receptors (GPCR), other receptors and also independently
(Andreeva et al, 2007). There are two distinct groups of G-proteins:
the large (heterotrimeric) form, and the small (monomeric) form,
otherwise known as the Ras superfamily of GTPases. The large
G-proteins exist at the cell surface next to the GPCR and are made
up of three sub units: a, b and g. Ligand binding and exchange of
GDP for GTP on the a-subunit allow signal transduction, which is
terminated by GTP hydrolysis back to GDP. The small GTPases
exist unbound to the GPCR. They contain an a-subunit with a
structurally homologous GTPase domain to that of the large
heterotrimeric G-proteins (Oldham and Hamm, 2006). Similarly,
their action depends upon the binding of GTP. Once activated,
they initiate signalling cascades, phosphorylating downstream
proteins and causing an effect. They are split further into five
families: Ras, Rho, Rab, Ran and Arf. We have shown that when
stimulated with androgens, a number of G-proteins are upregu-
lated in OVCAR3 cells. We investigated two of the small G-proteins
further: Rab25 and Rab35. We chose to examine Rab35 as this was
the most differentially expressed gene upon androgen stimulation,
and Rab25 as a comparison as this was only marginally altered in
response to androgens.
Rab25 is a small GTPase of 28 kDa, localised in epithelial cells.
It is involved in protein trafficking from the cell membrane to
cytoplasmic vesicles (Cheng et al, 2005), and is known to be
involved in proliferation, protection from apoptosis and invasion
in ovarian cancers (Yang et al, 2006). It has been shown to be
upregulated in 80% of ovarian cancers and its expression
correlates with a worse disease-free survival in both ovarian and
breast cancers (Cheng et al, 2004a, b).
Of interest is the observation that Rab25 expression is only
marginally upregulated after exposure to androgen, as an
androgen response element in the antisense strand of the Rab25
gene has been found (Louro et al, 2007). It is possible that effects
observed on Rab25 expression are mediated by an indirect
mechanism, perhaps through TGFb receptors, which have been
shown to interact with the AR in ovarian cancer (Evangelou et al,
2000). Furthermore, it has been proposed that endometrioid
tumours develop as a result of TGFbR-II (Lynch et al, 1998) and
MSH2 (Fujita et al, 1995) mutations rather than mutations of
k-Ras (Enomoto et al, 1991). Our finding, therefore, that Rab25
expression is greatest in endometrioid tumours does not rule out
a possible indirect interaction between androgen stimulation, the
TGFb receptors and Rab25.
Another small GTPase, Rab35, was the most upregulated upon
androgen stimulation in our experiments. Little is known about
this protein, although it is thought to be involved in endocytic
recycling (Kouranti et al, 2006) and may play a role in the
modulation of p53 by regulating the p53-related protein kinase,
PRPK, giving it oncogenic potential (Abe et al, 2006). We have not
shown any clinical significance related to Rab35 expression,
although 95% of the tumours examined showed expression of
Table 3 Correlation of expression of Rab25 and Rab35 with clinical
parameters
Rab25 Rab35 AR
Variable n (%) Median P Median P Median P
Available to score 154
Stage 0.78 0.76 0.6
I 27 (17.5) 7 4.7 7.25
II 14 (9) 11.3 4.5 11.25
III 91 (59) 7.5 4.7 7.5
IV 18 (12) 7.8 5.7 8.25
Missing 4 (3)
Grade 0.49 0.58 0.75
1 38 (25) 7 5.5 7.5
2 41 (27) 7.8 4 8.5
3 75 (49) 7.5 4.7 7.5
Missing 0
Histological subtypes 0.001 0.32 0.02
Serous 73 (47) 7.5 5 7.5
Mucinous 16 (10) 5.3 3.7 5.25
Endometrioid 47 (31) 10.3 5.3 10.5
Clear cell 15 (10) 5.8 6.1 6
Missing 3 (2)
Residual disease 0.56 0.32 0.4
None 54 (35) 8.5 4.7 9
p1 cm 30 (19) 8.5 4.8 8.5
41 cm 64 (42) 7 5 7
Missing 6 (4)
AR¼ androgen receptor.
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Figure 4 High expression of Rab25 predicts survival by histological type. (A) Kaplan–Meier survival curves of all patients included in this study show
differential expression by histological type. (B) Kaplan–Meier curves of only those tumours showing low expression of Rab25 shows no difference in survival
(C) Kaplan–Meier curves of only those tumours showing high expression of Rab25 attenuates this finding with improved survival in mucinous and
endometrioid tumours compared with serous and clear cell cancers (P¼ 0.043).
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the protein. The finding that Rab35 and AR expression correlate
supports the concept that Rab35 is an androgen responsive gene,
and given the timescale of upregulation after androgen stimula-
tion, it is likely that this is a direct effect. Further work is required
to investigate the functional role of Rab35 in ovarian cancer, but
this gene may have use as a biomarker of AR function in ovarian
cancer, thus being able to predict those patients who are likely to
respond to antiandrogen therapy.
Taken together, these data suggest that androgen treatment has
downstream effects on small G-protein signalling cascades,
however, this effect only occurs in a subset of ovarian cancers.
Further work is required to investigate these effects, and to identify
whether there is a subset of ovarian cancers in which this is
important, which may be suitable for a targeted antiandrogen
therapy.
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